skafather84 wrote:
the biggest harm of capitalism has been in the medical sector. an area where coming up with true results yields only negative return. if you only treat part of a disease/virus or only treat the symptoms, you make much more money than curing anyone...which is why we don't have real cures yet and haven't had a real cure for anything since the 1950s.
it's easier to make money in the medical business when your customers never get better and have to keep buying your faulty medicine.
I assume you define a real cure as a process that can be used
to treat a condition short term with no long term need for farther treatment. Such as some antibiotics can cure a some bacteria infections. In the case of new antibiotics your logic holds as
there is no real incentive to developed such drugs that might
have a short life span due to drug resistance bacteria evolving
and no long term need for maintenance doses.
I think where your logic break down is you do not understand
the realities of most medication conditions. For example in sickle cell anemia the hemoglobin in red blood cells is modified slightly and has lower solubility in water. So it deforms the cell in to a
sickle shape. There is a cure available though. A bone marrow transplant. Which could also be used to treat a lot different blood related cancers to. But available matches for most people is very low. So your telling me no one at the largest biotechnology companies are trying to developed a universal bone marrow because it would be bad for business? The answer
is they are trying its just hard.
In the case of most conditions the underlying mechanism is
not even well enough understood to know what the hard to
make cure might even be. There is no equivalent "universal
bone marrow" research target for most conditions.
The reality is for most conditions the economic disincentive arguments that applies to anti-biotic does not apply to them.
A "cure" based product could make money the entire life of the patent. For a novel solution to a problem the pharmaceuticals companies could charge what the market would bare. So if a single pill did the work of $30,000 worth of pills over ten years a company
could charge $10,000 for it easily. You can pay that a month for some limited market sized patented drugs today.